EUCTR2006-000704-17-ES进行中（未招募）不适用
Estudio internacional multicéntrico, doble ciego, aleatorizado, de grupos paralelos, con control activo y de 12 meses de duración para comparar la eficacia y seguridad de 0.5 mg y 1.25 mg de fingolimod (FTY720) administrado por vía oral una vez al día respecto a interferon Beta-1a (Avonex®) administrado por vía i.m una vez a la semana, en pacientes con esclerosis múltiple remitente-recurrente - D2302
ovartis Farmacéutica, S.A.0 个研究点目标入组 1,275 人开始时间: 2006年6月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,275
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. male or female;
- •females of childbearing potential must: have negative pregnancy tests prior to entry into the Double-Blind Treatment Phase, or be either post-menopausal for 12 months prior to Randomization or surgically sterile, or use adequate contraception during the treatment and 3 months after discontinuation of the study medication
- •2. 18 through 55 years of age inclusive
- •3. signed written informed consent prior to participating in the study.
- •Multiple sclerosis
- •4. diagnosis of multiple sclerosis as defined by 2005 revised McDonald criteria
- •5. a relapsing-remitting course with at least 1 documented relapse during the previous year or 2 documented relapses during the previous 2 years; prior to randomization
- •6. an Expanded Disability Status Scale (EDSS) score of 0-5.5 inclusive
- •7. neurologically stable with no evidence of relapse or corticosteroid treatment within 30 days prior to randomization
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet any of the following exclusion criteria during the Pre-Randomization Phase will not be eligible for enrollment in the study:
- •1. a manifestation of MS other than RRMS
- •2. a history of chronic disease of the immune system other than MS or a known
- •immunodeficiency syndrome
- •3. a history of epileptic seizures within 3 months of randomization
- •4. a history or presence of malignancy (except for successfully treated basal or squamous cell carcinoma of skin)
- •5. a known or ‘new’ diagnosis of diabetes mellitus
- •6. a diagnosis of macular edema during Pre-randomization Phase (patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at the ophthalmic screening visit).
- •7. active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests, respectively
- •8. have received total lymphoid irradiation or bone marrow transplantation
- •9. have been treated with:
- •corticosteroids or adrenocorticotropic hormones (ACTH) within 1 month prior to randomization
- •immunosuppressive medications such as azathioprine or methotrexate within 6 months prior to randomization
- •immunoglobulins and/or monoclonal antibodies (including natalizumab) within 6 months prior to randomization
- •cladribine, cyclophosphamide or mitoxantrone at any time
- •10. any medically unstable condition, as assessed by the primary treating physician
- •11. any of the following cardiovascular conditions:
- •myocardial infarction within the past 6 months prior to enrollment or current unstable ischemic heart disease
- •history of angina pectoris due to coronary spasm or history of Raynaud’s phenomenon
- •cardiac failure at time of Screening (Class III, according to NYHA Classification; or any severe cardiac disease as determined by the investigator
- •history of cardiac arrest
- •history of symptomatic bradycardia
- •resting pulse rate <55 bpm prior to randomization
- •history of sick sinus syndrome or sino-atrial heart block
- •history or presence of a second degree AV block or a third degree AV block or an increased QTc interval >440 ms on Screening ECG
- •arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide)
- •history of a positive tilt test from workup for vasovagal syncope
- •hypertension, uncontrolled by medication
- •12. any of the following pulmonary conditions:
- •severe respiratory disease or pulmonary fibrosis
- •tuberculosis, except for history of successfully treated tuberculosis or history of prophylactic treatment after positive PPD skin reaction
- •abnormal chest High Resolution Computer Tomography (HRCT) [or chest x-ray in case HRCT is not permitted by local regulations] suggestive of active pulmonary
- •abnormal Pulmonary Function Tests: FEV1;, FVC values lower than 70% of predicted value, DLCO values lower than 60% of predicted value
- •patients receiving daily therapies for asthma
- •13. any of the following hepatic conditions:
- •known history of alcohol abuse, chronic liver or biliary disease, with the exception of Gilbert’s syndrome
- •total or conjugated bilirubin greater than the upper limit of the normal range
- •alkaline phosphatase (AP) greater than 1.5 times the upper limit of the normal range
- •AST (SGOT), ALT (SGPT) greater than 2 times the upper limit of the normal range
- •gamma-glut
研究者
相似试验
进行中（未招募）
1 期
Estudio internacional multicéntrico, doble ciego, aleatorizado, en grupos paralelos, con control histórico, de conversión a monoterapia, para evaluar la eficacia y seguridad de brivaracetam en pacientes (= 16 a 75 años de edad) que sufran crisis de inicio parcial con o sin generalización secundaria.(An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization).EUCTR2008-000145-58-ESCB Pharma S.A.62
进行中（未招募）
1 期
Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de liberación prolongada (ER) y el laropiprant (ERN/LRPT) en pacientes con dislipidemia. A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia;Dyslipidemia. DislipidemiaMedDRA version: 9 Level: LLT Classification code 10058108 Term: DyslipidaemiaEUCTR2009-012772-27-ESMerck & Co., Inc.1,125
进行中（未招募）
1 期
Estudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo y de 16 semanas de duración para comparar la eficacia y la seguridad de UT-15C en comprimidos orales de liberación prolongada en combinación con un antagonista del receptor de la endotelina y/o con un inhibidor de la fosfodiesterasa-5 en sujetos con hipertensión arterial pulmonarA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CHAP idiopática o familiar incluyendo HAP asociada a:1) Uso de un inhibidor del apetito2) Corticircuito sistémico-pulmonar congénito corregido (corrección = 5 años)3) HAP asociada a enfermedad del tejido conjuntivo vascular4) HIVMedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000800-17-ESnited Therapeutics Corporation300
进行中（未招募）
不适用
?Estudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia, la seguridad y la tolerabilidad de MK-0736 añadido al tratamiento en curso con un inhibidor de la enzima convertidora de la angiotensina (IECA) o con un antagonista del receptor de la angiotensina (ARA) en pacientes con diabetes e hipertensión?A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension - MK-0736 Dose Ranging StudyEUCTR2008-004831-39-ESMerk & Co., Inc567
进行中（未招募）
不适用
ESTUDIO MULTINACIONAL, MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO Y DE GRUPOS PARALELOS PARA COMPARAR LA SEGURIDAD Y LA EFICACIA DE 200 mg DE PAR-101 CADA 12 HORAS CON 125 mg DE VANCOMICINA CADA 6 HORAS DURANTE DIEZ DÍAS EN SUJETOS CON DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILEA multi-national, multi-centre, double-blind, randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects with Clostridium Difficile-associated diarrhea - A double-blind, randomised study of PAR-101 vs vancomycin in CDADDIARREA ASOCIADA A CLOSTRIDIUM DIFFICILEClostridium difficile associated diarrhoea (CDAD)MedDRA version: 8.1Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileEUCTR2006-004291-12-ESPar Pharmaceutical, Inc.664